At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
LY3039478drug
Likely dose
Not stated in record
Key inclusion· 5
- ✓Histologically or cytologically confirmed advanced and/or metastatic solid tumor
- ✓Failed standard therapy or standard therapy deemed not appropriate by investigator
- ✓ECOG performance status 0-1
- ✓Adequate hematologic, hepatic, and renal organ function
Key exclusion· 5
- ✕Chemotherapy within 14 days (nonmyelosuppressive) or 21 days (myelosuppressive)
- ✕Serious preexisting medical conditions
- ✕Active gastrointestinal disease with chronic or intermittent diarrhea (within 3 months)
- ✕Active bacterial, fungal, or known viral infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY3039478 in Japanese Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating LY3039478 for Advanced Solid Tumor. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartSep 2016
Primary CompletionJul 2019
Study CompletionMay 2023
TodayJul 2026
First PostedJul 19, 2016
Enrollment StartSep 9, 2016
Primary CompletionJul 5, 2019
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.0 years ago
Interventions
LY3039478drug
Administered orally